These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9075110)

  • 1. Ouabain and hypertension.
    de Wardener HE
    Nephrol Dial Transplant; 1997 Mar; 12(3):384-5. PubMed ID: 9075110
    [No Abstract]   [Full Text] [Related]  

  • 2. The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension.
    Blaustein MP; Zhang J; Chen L; Song H; Raina H; Kinsey SP; Izuka M; Iwamoto T; Kotlikoff MI; Lingrel JB; Philipson KD; Wier WG; Hamlyn JM
    Hypertension; 2009 Feb; 53(2):291-8. PubMed ID: 19104005
    [No Abstract]   [Full Text] [Related]  

  • 3. Endogenous Ouabain: Recent Advances and Controversies.
    Hamlyn JM; Blaustein MP
    Hypertension; 2016 Sep; 68(3):526-32. PubMed ID: 27456525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of the Na+, K+, and ATP binding sites of the ouabain-complexed (Na+ + K+)-ATPase: implications for the mechanism of ouabain action.
    Kakar SS; Huang WH; Askari A
    Prog Clin Biol Res; 1988; 268A():211-8. PubMed ID: 2843864
    [No Abstract]   [Full Text] [Related]  

  • 5. Signaling mechanisms that link salt retention to hypertension: endogenous ouabain, the Na(+) pump, the Na(+)/Ca(2+) exchanger and TRPC proteins.
    Blaustein MP; Hamlyn JM
    Biochim Biophys Acta; 2010 Dec; 1802(12):1219-29. PubMed ID: 20211726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of sodium intake, the Na+-K+ pump and a ouabain-like humoral agent in the genesis of reduced renal mass hypertension.
    Huot SJ; Pamnani MB; Clough DL; Haddy FJ
    Am J Nephrol; 1983; 3(2-3):92-9. PubMed ID: 6307048
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.
    Pullen MA; Brooks DP; Edwards RM
    J Pharmacol Exp Ther; 2004 Jul; 310(1):319-25. PubMed ID: 14982968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of binding of [3H]ouabain to smooth muscle sodium-potassium adenosine triphosphatase and quantitation of sodium-potassium pump sites.
    Gerthoffer WT; Allen JC
    J Pharmacol Exp Ther; 1981 Jun; 217(3):692-6. PubMed ID: 6262494
    [No Abstract]   [Full Text] [Related]  

  • 9. Parameters of [3H]-ouabain binding to human heart (Na+ + K+)-ATPase [proceedings].
    de Pover A; Godfraind T
    Br J Pharmacol; 1979 Jul; 66(3):471P-472P. PubMed ID: 230880
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemical, experimental, and clinical studies on endogenous ouabain-like substance in hypertension.
    Cloix JF; Crabos M; Devynck MA; Elghozi JL; Henning G; Kamal LA; Lacerda-Jacomini LC; Meyer P; Pernollet MG; Rosenfeld JB
    Adv Nephrol Necker Hosp; 1985; 14():161-71. PubMed ID: 2579533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of ouabain to the Na-K-ATPase in oocytes of Xenopus laevis is voltage-independent.
    Lafaire AV; Schweigert B; Schwarz W
    Prog Clin Biol Res; 1988; 268B():409-16. PubMed ID: 2851819
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-potassium pump inhibitor in the mechanism of one-kidney, one wrap hypertension in dogs.
    Pamnani MB; Swindall BT; Schooley JF; Ghai R; Haddy FJ
    Cell Mol Biol (Noisy-le-grand); 1999 Feb; 45(1):115-21. PubMed ID: 10099845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of chlormadinone acetate with the ouabain binding site of Na+,K+-ATPase.
    Wehling M; Schwartz A; Whitmer K; Grupp G; Grupp IL; Wallick ET
    Mol Pharmacol; 1981 Nov; 20(3):551-7. PubMed ID: 6173736
    [No Abstract]   [Full Text] [Related]  

  • 14. The binding of 3H-ouabain to Na+-K+ ATPase sites in arterial smooth muscle.
    Deth RC; Lynch CJ
    Pharmacology; 1980; 21(1):29-37. PubMed ID: 6250171
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of the frequency of rhythmic excitation on ouabain binding by giant squid axons].
    Maksimov GV; Fedorov GE; Kol's OR
    Biofizika; 1980; 25(2):307-8. PubMed ID: 6245731
    [No Abstract]   [Full Text] [Related]  

  • 16. Individual variability in membrane sodium transport during salt loading--evidence against the production of a Na+-K+-ATPase inhibitor in hypertension.
    Maling TJ; Siebers RW
    Prog Biochem Pharmacol; 1988; 23():91-100. PubMed ID: 2847194
    [No Abstract]   [Full Text] [Related]  

  • 17. Distances between 5-iodoacetamidofluorescein and the ATP and ouabain sites of (Na,K)-ATPase determined by fluorescence energy transfer.
    Fortes PA; Aguilar R
    Prog Clin Biol Res; 1988; 268A():197-204. PubMed ID: 2843862
    [No Abstract]   [Full Text] [Related]  

  • 18. Na+, K+-ATPase and ouabain binding activities of chick embryo dorsal root ganglia supported by and deprived of nerve growth factor.
    Skaper SD; Varon S
    J Neurosci Res; 1981; 6(1):133-41. PubMed ID: 6260964
    [No Abstract]   [Full Text] [Related]  

  • 19. [3H]ouabain binding and Na+-K+-ATPase activity in human placenta.
    Whitsett JA; Wallick ET
    Am J Physiol; 1980 Jan; 238(1):E38-45. PubMed ID: 6243875
    [No Abstract]   [Full Text] [Related]  

  • 20. Endogenous digitalis-like compound in essential hypertension.
    Devynck MA; Pernollet MG; De The H; Rosenfeld JB; Meyer P
    Proc Eur Dial Transplant Assoc; 1983; 20():489-95. PubMed ID: 6318222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.